Literature DB >> 27375322

Comparative Study of Predeposit and Bedside Leucodepletion Filters.

A Sen1, A Khetarpal Sm2, S Jetley3.   

Abstract

BACKGROUND: Removal of leucocytes from cellular blood components is associated with reduction of several transfusion associated adverse reactions.
METHODS: A total of 400 units of packed red blood cells (RBCs) were subjected to leucodepletion at room temperature and 4°C using different commercially available prestorage and bedside filters (Terumo Penpol Immugard III and Pall Medical BPF-4). Pre-filtration and post-filtration parameters were compared to assess the efficacy of prestorage leucodepletion vis-à-vis bedside leucodepletion and the requirement of universal leucodepletion. RESULT: Mean post-filtration red cell recovery ranged from 88.49-93.49% with all bags showing more than 85% red cell recovery. Mean post-filtration residual leucocyte count ranged from 0.205 × 10(6)-0.338 × 10(6)/bag with all bags showing more than log 3 leucoreduction. Prestorage leucoreduction achieved by the polyurethane filter was better than that achieved by the polyester filter. Red cell recovery with the bedside filters at room temperature was significantly less than that with prestorage filters at either temperature.
CONCLUSION: This study suggests that prestorage leucoreduction is preferable over bedside leucoreduction and that polyurethane filters are better than polyester filters since leucodepletion achieved with the former is higher. We recommend selective log 3 leucodepletion using polyurethane prestorage filters for patients with specific indications.

Entities:  

Keywords:  Leucodepletion; Polyurethane; Pre-storage

Year:  2011        PMID: 27375322      PMCID: PMC4920927          DOI: 10.1016/S0377-1237(10)80127-3

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  10 in total

Review 1.  Leukocyte reduction of blood components: public policy and new technology.

Authors:  S Dzik; J Aubuchon; L Jeffries; S Kleinman; C Manno; M F Murphy; M A Popovsky; M Sayers; L E Silberstein; S J Slichter; E C Vamvakas
Journal:  Transfus Med Rev       Date:  2000-01

Review 2.  Prevention of transfusion-associated graft-versus-host disease.

Authors:  G Moroff; N L Luban
Journal:  Transfusion       Date:  1992-02       Impact factor: 3.157

3.  Leukocyte depletion of red cell concentrates by filtration: influence of blood product temperature.

Authors:  F Beaujean; J M Segier; C le Forestier; N Duedari
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

4.  Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.

Authors:  M van Marwijk Kooy; H C van Prooijen; M Moes; I Bosma-Stants; J W Akkerman
Journal:  Blood       Date:  1991-01-01       Impact factor: 22.113

Review 5.  Clinical and laboratory precautions that reduce the adverse reactions, alloimmunization, infectivity, and possibly immunomodulation associated with homologous transfusions.

Authors:  B Wenz
Journal:  Transfus Med Rev       Date:  1990-10

6.  A new tool in white blood cell reduction for packed red cells: 5 log depletion.

Authors:  A Bontadini; F Fruet; R Conte
Journal:  Transfus Med       Date:  1997-03       Impact factor: 2.019

7.  Effects of 3-5 log10 pre-storage leucocyte depletion on red cell storage and metabolism.

Authors:  W A Heaton; S Holme; K Smith; M E Brecher; A Pineda; J P AuBuchon; E Nelson
Journal:  Br J Haematol       Date:  1994-06       Impact factor: 6.998

8.  "Guidance for Industry: For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and for the Completion of the Form FDA 356h, 'Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use;'" availability. Food and Drug Administration, HHS. Notice.

Authors: 
Journal:  Fed Regist       Date:  1999-05-10

9.  A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.

Authors:  R A Bowden; S J Slichter; M Sayers; D Weisdorf; M Cays; G Schoch; M Banaji; R Haake; K Welk; L Fisher; J McCullough; W Miller
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

10.  Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage.

Authors:  M T Aye; D S Palmer; A Giulivi; S Hashemi
Journal:  Transfusion       Date:  1995-02       Impact factor: 3.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.